immuno-neurology

Current Therapeutic Approach

Current experimental therapies target Tau tangles or Amyloid beta (AB) aggregates only. We believe this to be insufficient to make a real impact for patients.

Current experimental therapies target Tau tangles or Amyloid beta (AB) aggregates only. We believe this to be insufficient to make a real impact for patients.

Alector's Therapeutic Approach

Alector's programs harness the body's innate immune cells, the microglia, to counteract multiple pathologies simultaneously.

Alector's programs harness the body's innate immune cells, the microglia, to counteract multiple pathologies simultaneously.

There is a gap in our understanding of the mechanism of neuro-degenerative disease. Historically, we believed that microglia, immune cells in the brain, were merely responding to disease. A few years ago, genome-wide association studies (GWAS) identified new gene variants that increase or decrease the chance of developing neuro-degenerative disease. Surprisingly, a large fraction of these are immune genes primarily expressed in the microglia, suggesting that these cells not only respond to disease, but can also actively drive neuronal degeneration. By targeting immune genes tied to these specific diseases, we can improve the function of the immune system and halt progression of the disease.

 
In other fields, the therapies that have proven successful are those with either a strong genetic or mechanistic link to the disease.
— Tina Schwabe, Head of Immuno-neurology